Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Potential attenuation of disease progression in recurrent prostate cancer with plant-based diet and stress reduction.

Saxe GA, Major JM, Nguyen JY, Freeman KM, Downs TM, Salem CE.

Integr Cancer Ther. 2006 Sep;5(3):206-13.

PMID:
16880425
2.

Adoption of a plant-based diet by patients with recurrent prostate cancer.

Nguyen JY, Major JM, Knott CJ, Freeman KM, Downs TM, Saxe GA.

Integr Cancer Ther. 2006 Sep;5(3):214-23.

PMID:
16880426
3.

Biological mediators of effect of diet and stress reduction on prostate cancer.

Saxe GA, Major JM, Westerberg L, Khandrika S, Downs TM.

Integr Cancer Ther. 2008 Sep;7(3):130-8. doi: 10.1177/1534735408322849.

4.

Can diet in conjunction with stress reduction affect the rate of increase in prostate specific antigen after biochemical recurrence of prostate cancer?

Saxe GA, Hébert JR, Carmody JF, Kabat-Zinn J, Rosenzweig PH, Jarzobski D, Reed GW, Blute RD.

J Urol. 2001 Dec;166(6):2202-7.

PMID:
11696736
5.

Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.

Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB.

Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1520-9.

PMID:
15050332
7.

Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy.

D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH.

J Urol. 2004 Nov;172(5 Pt 2):S42-6; discussion S46-7.

PMID:
15535442
8.

PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.

Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H.

Mayo Clin Proc. 2001 Jun;76(6):576-81.

PMID:
11393495
9.

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.

Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A.

Lancet Oncol. 2014 Sep;15(10):1076-89. doi: 10.1016/S1470-2045(14)70328-6. Epub 2014 Aug 14.

PMID:
25130995
10.

The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy.

Trapasso JG, deKernion JB, Smith RB, Dorey F.

J Urol. 1994 Nov;152(5 Pt 2):1821-5.

PMID:
7523728
11.

Early outcomes of active surveillance for localized prostate cancer.

Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R, Dearnaley D.

BJU Int. 2005 May;95(7):956-60.

12.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
13.

Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS).

Schröder F, Bangma C, Angulo JC, Alcaraz A, Colombel M, McNicholas T, Tammela TL, Nandy I, Castro R.

Eur Urol. 2013 May;63(5):779-87. doi: 10.1016/j.eururo.2012.11.006. Epub 2012 Nov 12.

PMID:
23176897
15.

Dutasteride monotherapy in men with serologic relapse following radical therapy for adenocarcinoma of the prostate: a pilot study.

Perrotti M, Jain R, Abriel LM, Baroni TE, Corbett AB, Tenenbaum SA.

Urol Oncol. 2012 Mar-Apr;30(2):133-8. doi: 10.1016/j.urolonc.2010.01.004. Epub 2010 Aug 25.

PMID:
20800512
16.

Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy.

Barqawi AB, Moul JW, Ziada A, Handel L, Crawford ED.

Urology. 2003 Nov;62(5):872-6.

PMID:
14624911
17.

Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer.

deVere White RW, Hackman RM, Soares SE, Beckett LA, Li Y, Sun B.

Urology. 2004 Feb;63(2):259-63.

PMID:
14972467
18.

Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.

Soergel TM, Koch MO, Foster RS, Bihrle R, Wahle G, Gardner T, Jung SH.

J Urol. 2001 Dec;166(6):2198-201.

PMID:
11696735
19.

HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.

Asimakopoulos AD, Miano R, Virgili G, Vespasiani G, Finazzi Agrò E.

Urol Oncol. 2012 Sep;30(5):577-83. doi: 10.1016/j.urolonc.2010.08.019. Epub 2011 Feb 2.

PMID:
21292508
20.

Supplemental Content

Support Center